Cargando…
Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial
The aim of this study is to investigate the glycemic profile, oxidative stress, and antioxidant capacity in athletes after 12 weeks of ubiquinone supplementation. It was a double-blinded, randomized, parallel, placebo-controlled study. Thirty-one well-trained college athletes were randomly assigned...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555239/ https://www.ncbi.nlm.nih.gov/pubmed/32899227 http://dx.doi.org/10.3390/antiox9090823 |
_version_ | 1783593961408954368 |
---|---|
author | Ho, Chien-Chang Chang, Po-Sheng Chen, Hung-Wun Lee, Po-Fu Chang, Yun-Chi Tseng, Ching-Yu Lin, Ping-Ting |
author_facet | Ho, Chien-Chang Chang, Po-Sheng Chen, Hung-Wun Lee, Po-Fu Chang, Yun-Chi Tseng, Ching-Yu Lin, Ping-Ting |
author_sort | Ho, Chien-Chang |
collection | PubMed |
description | The aim of this study is to investigate the glycemic profile, oxidative stress, and antioxidant capacity in athletes after 12 weeks of ubiquinone supplementation. It was a double-blinded, randomized, parallel, placebo-controlled study. Thirty-one well-trained college athletes were randomly assigned to ubiquinone (300 mg/d, n = 17) or placebo group (n = 14). The glycemic profile [fasting glucose, glycated hemoglobin (HbA1c), homeostatic model assessment-insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI)], plasma and erythrocyte malondialdehyde (MDA), total antioxidant capacity (TAC), and ubiquinone status were measured. After supplementation, the plasma ubiquinone concentration was significantly increased (p < 0.05) and the level of erythrocyte MDA was significantly lower in the ubiquinone group than in the placebo group (p < 0.01). There was a significant correlation between white blood cell (WBC) ubiquinone and glycemic parameters [HbA1c, r = −0.46, p < 0.05; HOMA-IR, r = −0.67, p < 0.01; QUICKI, r = 0.67, p < 0.01]. In addition, athletes with higher WBC ubiquinone level (≥0.5 nmol/g) showed higher erythrocyte TAC and QUICKI and lower HOMA-IR. In conclusion, we demonstrated that athletes may show a better antioxidant capacity with higher ubiquinone status after 12 weeks of supplementation, which may further improve glycemic control. |
format | Online Article Text |
id | pubmed-7555239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75552392020-10-19 Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial Ho, Chien-Chang Chang, Po-Sheng Chen, Hung-Wun Lee, Po-Fu Chang, Yun-Chi Tseng, Ching-Yu Lin, Ping-Ting Antioxidants (Basel) Article The aim of this study is to investigate the glycemic profile, oxidative stress, and antioxidant capacity in athletes after 12 weeks of ubiquinone supplementation. It was a double-blinded, randomized, parallel, placebo-controlled study. Thirty-one well-trained college athletes were randomly assigned to ubiquinone (300 mg/d, n = 17) or placebo group (n = 14). The glycemic profile [fasting glucose, glycated hemoglobin (HbA1c), homeostatic model assessment-insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI)], plasma and erythrocyte malondialdehyde (MDA), total antioxidant capacity (TAC), and ubiquinone status were measured. After supplementation, the plasma ubiquinone concentration was significantly increased (p < 0.05) and the level of erythrocyte MDA was significantly lower in the ubiquinone group than in the placebo group (p < 0.01). There was a significant correlation between white blood cell (WBC) ubiquinone and glycemic parameters [HbA1c, r = −0.46, p < 0.05; HOMA-IR, r = −0.67, p < 0.01; QUICKI, r = 0.67, p < 0.01]. In addition, athletes with higher WBC ubiquinone level (≥0.5 nmol/g) showed higher erythrocyte TAC and QUICKI and lower HOMA-IR. In conclusion, we demonstrated that athletes may show a better antioxidant capacity with higher ubiquinone status after 12 weeks of supplementation, which may further improve glycemic control. MDPI 2020-09-03 /pmc/articles/PMC7555239/ /pubmed/32899227 http://dx.doi.org/10.3390/antiox9090823 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ho, Chien-Chang Chang, Po-Sheng Chen, Hung-Wun Lee, Po-Fu Chang, Yun-Chi Tseng, Ching-Yu Lin, Ping-Ting Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title | Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_full | Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_fullStr | Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_full_unstemmed | Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_short | Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial |
title_sort | ubiquinone supplementation with 300 mg on glycemic control and antioxidant status in athletes: a randomized, double-blinded, placebo-controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555239/ https://www.ncbi.nlm.nih.gov/pubmed/32899227 http://dx.doi.org/10.3390/antiox9090823 |
work_keys_str_mv | AT hochienchang ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial AT changposheng ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial AT chenhungwun ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial AT leepofu ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial AT changyunchi ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial AT tsengchingyu ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial AT linpingting ubiquinonesupplementationwith300mgonglycemiccontrolandantioxidantstatusinathletesarandomizeddoubleblindedplacebocontrolledtrial |